Euclises
Novel cox-2 inhibitors for the effective treatment of cancers in the lungs, colon, and pancreas.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD7—11m (Dealroom.co estimates Dec 2016.)
St. Louis Missouri (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $180k | Seed | |
| N/A | $18.0k | Seed | |
$1.3m | Series A | ||
$700k | Series A | ||
| N/A | $2.0m | Seed | |
| N/A | $22.0k | Seed | |
$1.2m | Early VC | ||
| Total Funding | AUD8.4m | ||
Related Content
Recent News about Euclises
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.